Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Biochem. 2013 Jun;46(9):740-4. doi: 10.1016/j.clinbiochem.2012.12.017. Epub 2013 Jan 4.

Lipid profile changes by high activity anti-retroviral therapy.

Author information

1
Faculty of Pharmacy, Oporto University, Oporto, Portugal.

Abstract

OBJECTIVE:

Study of the lipid profile in patients infected with HIV treated with different combinations of high activity anti-retroviral therapy (HAART).

DESIGN AND METHODS:

A retrospective cohort study of the lipid profile in patients undergoing HAART. The study analyzes the evolution of concentrations of triglycerides (TG), total cholesterol (TC), LDL-cholesterol (LDLc) and HDL-cholesterol (HDLc) in a period of at least 3 years of treatment. From a total of 750 clinical cases analyzed in Hospital Joaquim Urbano (Oporto, Portugal) 124 patients were selected for this study.

RESULTS:

After 3 years of treatment, we observed the development of dyslipidaemia by increases in TG (17%), TC (29%) and LDLc (9%), particularly in patients treated with a combination of drugs which included protease inhibitors (PI). Moreover, the non-nucleoside reverse transcriptase inhibitors (NNRTI) were associated with better lipid profile. The increase of 46% in HDLc was the most surprising finding.

CONCLUSIONS:

The results indicate that patients with HAART have a more atherogenic lipidic profile with increased TC, LDLc and TG levels. Since the effectiveness of NNRTI is similar to that of PI, but with a smaller atherogenic profile, it should be the first choice drug to be selected in the HIV treatment.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center